Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
The lawsuits target a range of businesses that allegedly marketed retatrutide products to consumers despite the drug remaining under clinical development.
Overview
The lawsuits target a range of businesses that allegedly marketed retatrutide products to consumers despite the drug remaining under clinical development.
Source
Originally published at www.cnbc.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.